Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis

INTRODUCTION: Although the treatment paradigm for hepatocellular carcinoma (HCC) has recently shifted in favour of checkpoint inhibitor (CPI)-based treatment options, the tyrosine kinase inhibitors (TKI) currently approved for the treatment of HCC are expected to remain the cornerstone of HCC treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Sagmeister, Paula, Daza, Jimmy, Ofner, Andrea, Ziesch, Andreas, Ye, Liangtao, Ben Khaled, Najib, Ebert, Matthias, Mayerle, Julia, Teufel, Andreas, De Toni, Enrico N, Munker, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278726/
https://www.ncbi.nlm.nih.gov/pubmed/35845819
http://dx.doi.org/10.2147/JHC.S356333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278726/
https://www.ncbi.nlm.nih.gov/pubmed/35845819
http://dx.doi.org/10.2147/JHC.S356333

Ejemplares similares